"This amendment recognizes the potential future financing source represented by these warrants at a relatively low cost to the Company," said Dr.
The expiry date is being extended to
The Company will deliver a Notice of Amendment reflecting the amended expiry date to the registered holders of the Warrants.
COTI is a leading-edge bioinformatics company specializing in accelerating the discovery and development of small molecules - dramatically reducing the time and cost to bring new drugs to market. COTI's proprietary artificial intelligence system, CHEMSAS(R), utilizes a series of predictive computer models to identify compounds with a high probability of being successfully developed from disease specific drug discovery through chemical optimization and preclinical testing. These compounds are targeted for a variety of diseases, particularly those for which current treatments are either lacking or ineffective.
For more information, visit www.criticaloutcome.com.
Follow @CriticalOutcome on Twitter at http://twitter.com/CriticalOutcome.
FOR FURTHER INFORMATION PLEASE CONTACT:
Critical Outcome Technologies Inc.Dr. Wayne DanterPresident & CEO Tel: 519-858-5157 Email: firstname.lastname@example.org Heisler Communications Trevor HeislerInvestor Relations Tel: 416-500-8061 Email: email@example.com Source: Critical Outcome Technologies Inc.(COTI)